A New Frontier
TB Alliance Annual Report 2018 TREATMENT
Pretomanid Submitted to FDA
Pretomanid, a novel TB drug developed by TB Alliance, is under regulatory review. In December 2018, TB Alliance submitted its first-ever New Drug Application to the U.S. Food and Drug Administration. Pictured: the chemical structure of pretomanid.
Learn more
R&D
Three Late-Stage Clinical Trials Advancing TB Treatment
TB Alliance is working to introduce promising new TB treatments for all forms of the disease. In 2018, we concurrently led three late stage trials – each expected to offer scientific insights that could significantly impact the global epidemic.
Learn more Partnerships
UN High Level Meeting Sparks Global Commitments to Fight TB
In 2018, the United Nations (UN) held a High-Level Meeting (HLM) on Tuberculosis – only the fifth-ever time the UN devoted an HLM to a health issue.
Read more
TB Alliance in 2018
An overview of TB Alliance's progress in developing new treatment regimens for tuberculosis.
Developing New Treatments Annual Report 2018